VIR · Vir Biotechnology, Inc.
Market Cap
$1.80B
Shares
169.22M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$10.62
Open$10.79
Day$10.38–10.95
52W close$4.79–11.63
Avg vol 30d1.8M
Short int21.3M · 12.6% float · 11.1d
Short vol53%
Last earningsAug 5, 2026
DataJan 2020–Sep 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Nov 4, 2026
Est · unconfirmed
· in 8 wks
filed Aug 5, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$303.23M
Trailing 12 months
Net income (TTM)
−$251.68M
Trailing 12 months
Revenue growth YoY
+19,582.5%
Year over year
Operating margin
-92.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-11.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$528.59M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+22.0%
Year over year · more shares
Price change (1Y)
+106.2%
Trailing year
Short interest
12.6%
Latest settlement · 11.1 days to cover
AI Brief
Q2 FY26 earnings call · Aug 5, 2026
Q2 FY26
TL;DR. Vir Biotechnology reported Q2 2026 results highlighted by $80.1M net income driven by a $240M Astellas upfront payment, completed enrollment across all three Phase 3 ECLIPSE hepatitis delta registrational trials with Eclipse 1 topline data expected in Q4 2026, and Phase 2 SOLSTICE Week 96 data showing 88% HDV RNA target-not-detected with elebsiran plus tobevibart.
Bullish
- + Completed enrollment across all three Phase 3 ECLIPSE registrational trials in chronic hepatitis delta, with Eclipse 1 topline data expected Q4 2026.
- + Phase 2 SOLSTICE Week 96 data showed 88% HDV RNA target-not-detected rate with elebsiran plus tobevibart versus 53% on antibody monotherapy.
- + Closed Astellas collaboration and initiated multiple VIR-5500 Phase 1 monotherapy and combination dose-expansion cohorts, with pivotal Phase 3 planned for 2027.
- + Cash position increased by $198.5M to approximately $1.01 billion, with runway projected into second half of 2028.
- + Reported Q2 net income of $80.1M, or $0.48 per share basic, versus a net loss of $111.0M in Q2 2025.
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bearish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.60
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+22%
above
Price vs 50-day avg
+8%
above
RSI (14)
54
neutral
MACD trend
Negative
52-week position
85%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+18%
trailing
6-month return
+17%
trailing
YTD return
+76%
this year
Relative strength
−1%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $10 › 200d $9 — 50d above 200d
Institutional flow
Distributing
-6% holders QoQ · +32 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
12.61% of float · ▲ +8.9% MoM · 11.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
240 holders — mid 3-yr range
Squeeze score
79
high risk · 0–100
Fundamentals
Revenue growth
−8%
Y/Y
EPS growth
+17%
Y/Y
Free cash flow
$-396.6M
Quant / Vol
risk profile
Volatility
65%
annualized · 1-yr
Max drawdown
−26%
past year
ATR
5.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+22%
Bullish
Price vs 50-day avg
+8%
Bullish
RSI (14)
54
Neutral
MACD trend
Negative
Bearish
52-week position
85%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $10 › 200d $9 — 50d above 200d
Institutional flow
Distributing
-6% holders QoQ · +32 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
12.61% of float · ▲ +8.9% MoM · 11.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
240 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $5
Now $11 · 85%
Range high $12
vs 200-day avg +22%
vs 50-day avg +8%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VIR
this stock
Vir Biotechnology, Inc.
|
$1.80B | +76.1% | -7.6% | — | 12.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.64B | +13.7% | +46.2% | 30.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.46B | +1.2% | +20.8% | 19.4 | 2.5% |
|
ARGX
Argenx SE
|
$61.60B | +17.1% | — | — | 2.0% |
|
MRNA
Moderna, Inc.
|
$57.48B | +388.2% | +4.3% | — | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VIR | -7.3% | +18.0% | +16.7% | -2.9% | +76.1% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -6.1% | +19.8% | -1.1% | -2.6% | +64.0% |
Key facts
CIK
1706431
CUSIP
92764N102
13F (30d)
116 filings
116 filers
Visit website
Investor relations